Blood Science

Scope & Guideline

Transforming Understanding of Blood-Related Health Issues

Introduction

Immerse yourself in the scholarly insights of Blood Science with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2543-6368
PublisherLIPPINCOTT WILLIAMS & WILKINS
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2019 to 2024
AbbreviationBLOOD SCI / Blood Sci.
Frequency-
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Aims and Scopes

The journal 'Blood Science' focuses on advancing the understanding of hematological disorders, their underlying mechanisms, and the development of novel therapeutic strategies. Its research encompasses a wide range of topics in hematology, with an emphasis on molecular and cellular biology, translational research, and clinical applications.
  1. Hematological Malignancies:
    Research on various blood cancers, including acute myeloid leukemia, multiple myeloma, and lymphomas, focusing on their pathogenesis, genetic mutations, and novel treatment approaches.
  2. Translational Medicine:
    Studies bridging laboratory research and clinical practice, including the evaluation of new therapies, prognostic models, and treatment outcomes in hematological patients.
  3. Immune Modulation and Therapy:
    Exploration of immune mechanisms in hematology, including CAR-T cell therapy, immune checkpoint inhibitors, and the role of the immune microenvironment in blood disorders.
  4. Stem Cell Biology:
    Investigation of hematopoietic stem cells, their differentiation pathways, and the impact of the bone marrow niche on stem cell function and disorders.
  5. Epigenetics and Molecular Mechanisms:
    Research on the epigenetic modifications and molecular pathways involved in hematopoiesis and hematological diseases, shedding light on novel therapeutic targets.
  6. Iron Metabolism and Hematopathologies:
    Focus on iron regulation in the context of hematological disorders, examining its implications in diseases such as anemia and myelodysplastic syndromes.
  7. Microbiome and Hematopoiesis:
    Studies investigating the interactions between gut microbiota and hematopoietic processes, highlighting their influence on health and disease.
The journal has identified several emerging themes that reflect the latest advancements and interests in the field of hematology. These trends indicate a growing focus on innovative therapies, personalized medicine, and the molecular underpinnings of hematological diseases.
  1. Targeted Therapies and Precision Medicine:
    Increasing emphasis on the development and application of targeted therapies, including CAR-T cell therapy and small molecular inhibitors, to improve outcomes in hematological malignancies.
  2. Single-Cell Analysis Techniques:
    Emerging use of single-cell RNA sequencing and other advanced techniques to understand the heterogeneity of hematopoietic cells and their implications in disease progression.
  3. Gut Microbiota and Hematological Health:
    Growing interest in the role of gut microbiota in influencing hematopoiesis and the immune response, highlighting its potential as a therapeutic target.
  4. Epigenetic and Molecular Pathways:
    A surge in research focusing on epigenetic changes and molecular mechanisms that drive hematological conditions, providing insights into novel treatment strategies.
  5. Immune Microenvironment Reprogramming:
    Emerging studies targeting the tumor immune microenvironment, particularly macrophage reprogramming, to enhance immunotherapy efficacy in blood cancers.
  6. Biomarkers for Prognosis and Treatment Response:
    Increased focus on identifying biomarkers that can predict treatment response and disease prognosis, facilitating personalized treatment approaches in hematology.

Declining or Waning

While 'Blood Science' has seen a robust growth in specific research areas, some themes appear to be declining in prominence. These waning scopes suggest a shift in focus towards more contemporary and impactful areas in hematology.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decrease in studies focused solely on conventional chemotherapy regimens, as the field shifts towards more targeted and personalized treatment strategies.
  2. Historical Treatments for Hematological Disorders:
    Research centered on older treatment modalities, such as older immunosuppressive therapies or less effective transfusion methods, is becoming less common as new therapies emerge.
  3. Basic Hematology Studies:
    Basic studies that do not link findings to clinical applications or translational research are appearing less frequently, indicating a trend towards research that can directly impact patient outcomes.

Similar Journals

Therapeutic Advances in Hematology

Fostering collaboration for a healthier tomorrow.
Publisher: SAGE PUBLICATIONS LTDISSN: 2040-6207Frequency: 1 issue/year

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

CANCER JOURNAL

Advancing Cancer Research, One Study at a Time.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1528-9117Frequency: 6 issues/year

CANCER JOURNAL is a leading peer-reviewed publication dedicated to the dissemination of innovative research in the fields of cancer research and oncology. Published by Lippincott Williams & Wilkins, this journal serves as an essential resource for researchers, clinicians, and students seeking to advance their understanding of cancer mechanisms, treatment strategies, and patient care. With an ISSN of 1528-9117 and an E-ISSN of 1540-336X, it boasts a respectable 2023 Q2 category ranking in both Cancer Research and Oncology, reflecting its impactful contributions to the scientific community. Although it currently does not offer open access, the journal's rigorous peer-review process ensures the publication of high-quality, relevant studies that stimulate further investigation and collaboration among professionals. Since its inception, the journal has evolved through several converged years, maintaining a steadfast commitment to addressing the complexities of cancer biology and treatment. At its core, CANCER JOURNAL aims to foster advancements in oncology, making it a vital platform for sharing pivotal findings that could transform cancer research and therapeutic practices.

Indian Journal of Hematology and Blood Transfusion

Empowering Healthcare Through Cutting-edge Hematology Research
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

HEMATOLOGICAL ONCOLOGY

Exploring Breakthroughs in Cancer and Blood Disorders
Publisher: WILEYISSN: 0278-0232Frequency: 4 issues/year

HEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.

EXPERIMENTAL HEMATOLOGY

Exploring Innovations in Hematology and Beyond
Publisher: ELSEVIER SCIENCE INCISSN: 0301-472XFrequency: 12 issues/year

EXPERIMENTAL HEMATOLOGY, published by Elsevier Science Inc, is a leading journal in the field of hematology, distinguished by its impactful contributions to the study of blood-related disorders and cellular biology. With an ISSN of 0301-472X and an E-ISSN of 1873-2399, this journal has established a significant presence since its inception in 1973, continuing to be relevant through 2024. It holds a commendable Q1 ranking in Hematology and Q2 in various significant categories including Cancer Research, Cell Biology, Genetics, and Molecular Biology, recognizing its quality and influence in the scientific community. Researchers and professionals can access a wide range of meticulously peer-reviewed articles that promote cutting-edge research and foster collaboration across disciplines. As a vital platform for disseminating innovative findings, EXPERIMENTAL HEMATOLOGY empowers its audience to delve deeper into the complexities of hematological research and brings to light the advances critical for improving patient outcomes.

Hematology Transfusion and Cell Therapy

Empowering discoveries in transfusion medicine.
Publisher: ELSEVIERISSN: 2531-1379Frequency: 4 issues/year

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

Hematology-American Society of Hematology Education Program

Cultivating Expertise in Blood Health
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

CELL RESEARCH

Exploring Innovations in Molecular Biology
Publisher: SPRINGERNATUREISSN: 1001-0602Frequency: 12 issues/year

CELL RESEARCH is a premier peer-reviewed journal dedicated to advancing the field of cell biology and molecular biology, published by SpringerNature. With an impressive impact factor and consistently ranking in the Q1 quartile for both cell biology and molecular biology, this journal serves as a pivotal resource for researchers, professionals, and students seeking to explore the latest discoveries and advancements in cellular mechanisms and their implications for health and disease. Since its inception in 1996, CELL RESEARCH has cultivated a distinguished reputation, currently boasting ranks in the top percentile of Scopus categories, reaffirming its influence and relevance to the scientific community. Although it is not an Open Access journal, its rigorous selection process ensures the publication of high-quality articles that contribute significantly to our understanding of life sciences. For those deeply engaged in the realms of biochemistry, genetics, and molecular biology, CELL RESEARCH is an essential conduit of innovative research and critical insights.

Hematologie

Empowering the Future of Hematological Sciences
Publisher: JOHN LIBBEY EUROTEXT LTDISSN: 1264-7527Frequency: 6 issues/year

Hematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.

Cancer Discovery

Advancing the Frontiers of Oncology Research
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2159-8274Frequency: 12 issues/year

Cancer Discovery, published by the American Association for Cancer Research, stands as a vital resource in the oncological research community, renowned for its commitment to disseminating groundbreaking studies and innovative findings in cancer biology, prevention, diagnostics, and treatment. With a significant impact factor reflecting its esteemed position, this journal facilitates open discussions and collaborations, striving to bridge the gap between experimental and clinical research. The journal, which has been active since 2011, is classified as a Q1 publication in 2023, underscoring its influence and authority in the realm of Oncology. By providing a platform for rigorous peer-reviewed articles, Cancer Discovery aims to advance our understanding of cancer and enhance therapeutic strategies, making it an indispensable tool for researchers, professionals, and students eager to stay at the forefront of cancer research.